

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee 1. Mercy Memorial Hospital 2. 718 N Macomb St. Monroe, MI 48162		In accordance with application dated April 08, 2021, 3. License No.: 21-18816-01 is amended in its entirety to read as follows:	4. Expiration Date: November 30, 2021 5. Docket No.: 030-14210 Reference No.:
6. Byproduct, source, and/or special nuclear material A. Any byproduct material permitted by 10 CFR 35.100 B. Any byproduct material permitted by 10 CFR 35.200 C. Any byproduct material permitted by 10 CFR 35.300 D. Any byproduct material permitted by 10 CFR 31.11	7. Chemical and/or physical form A. Any B. Any C. Any D. Prepackaged Kits	8. Maximum amount that licensee may possess at any one time under this license A. As Needed B. As Needed C. 1 curie total D. 5 millicuries total	9. Authorized use A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100. B. Any imaging and localization study permitted by 10 CFR 35.200. C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300. D. In vitro studies.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 21-18816-01

Docket or Reference No.:
030-14210

Amendment No. 28

CONDITIONS

10. Licensed material shall be used or stored at the licensee's facilities located at 718 North Macomb Street, Monroe, Michigan, 48162.
11. The Radiation Safety Officer for this license is Sven Gallo, M.Sc.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
 - B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User (M.D., D.O., etc.)Material and Use

Matthew G. Aagesen, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

Debra Achinger, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

Zakaria Ismail Assi, M.D.

10 CFR 35.100, 10 CFR 35.200

Garett Begeman, M.D.

10 CFR 35.100, 10 CFR 35.200

Paul Berlacher, M.D.

10 CFR 35.200

Jacob Bieszczad, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

James F. Bingle, M.D.

10 CFR 35.200

David R. Cervantes, M.D.

10 CFR 35.100, 10 CFR 35.200

Donald L. Cox, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

Amy Culler, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

Laura DeBenedetti, M.D.

10 CFR 35.200

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 21-18816-01

Docket or Reference No.:
030-14210

Amendment No. 28

Authorized User (M.D., D.O., etc.)Material and Use

Daniel Dessner, M.D.

10 CFR 35.100, 10 CFR 35.200

Robert DiSalle, M.D.

10 CFR 35.100, 10 CFR 35.200

Malcolm Doyle, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

Farhad Ebrahim, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

Nathan Egbert, M.D.

10 CFR 35.100, 10 CFR 35.200

Stephen Eldridge, M.D.

10 CFR 35.100, 10 CFR 35.200

Haitham M. Elsamaloty, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

Carolyn S. Gbur, M.D.

10 CFR 35.200

Murray Howe, M.D., Ph.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

Mark G. Issa, D.O.

10 CFR 35.200

Adil M. Karamali, M.D.

10 CFR 35.200

Vincent Keiser, M.D.

10 CFR 35.100, 10 CFR 35.200

Steven Kumar-Jindal, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

John R. Letcher, M.D.

10 CFR 35.200

Terrence Lewis, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

Peter J. Longabaugh, M.D.

10 CFR 35.200

Mohammed Maaieh, M.D.

10 CFR 35.200

Tamara Martin, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

Tarek S. Moustafa, M.D.

10 CFR 35.100, 10 CFR 35.200

Jonathan Nadaud, M.D.

10 CFR 35.100, 10 CFR 35.200

Thomas Pappas, M.D.

10 CFR 35.200

Parag Parikh, M.D.

10 CFR 35.100, 10 CFR 35.200

Yogesh P. Patel, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 21-18816-01

Docket or Reference No.:
030-14210

Amendment No. 28

Authorized User (M.D., D.O., etc.)

Timothy Quinn, M.D.

Steven K. Shekut, M.D.

Robin Shermis, M.D.

Bruce R. Siders, D.O.

Stephen Stoll, M.D.

Michael A. Walsh, M.D.

Thomas T. Win, M.D.

Jonathan Yobbagy, M.D.

Material and Use

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

10 CFR 35.100, 10 CFR 35.200

10 CFR 35.100, 10 CFR 35.200

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

10 CFR 35.100, 10 CFR 35.200



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 21-18816-01

Amendment No. 28

Docket or Reference No.:
030-14210

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those statements, representations, and procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence impose on the licensee requirements that are more restrictive than or in addition to the regulations.

- A. Application dated July 15, 2011 (ML111990553)
- B. Letter dated October 14, 2014 (ML14289A517)
- C. Letter dated January 16, 2015 (ML15021A472)
- D. Letter dated February 4, 2015 (ML15036A571)
- E. Application dated January 6, 2017 (ML17009A284)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: June 7, 2021By: _____
Frank P. D. Tran
Region 3